LATEST UPDATES » Big Data, Bigger Disease Management and Current preparations to manage the Future Health of Singaporeans       » Big Data in Clinical Research Sector       » Professor Yuk-ling Yung receives Gerard P. Kuiper Prize       » AXA Assistance on Regenerative Medicine       » Singtel – Singapore Cancer Society Race against Cancer 2015       » Jardiance® is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death      
BioScience Managers banks on growth of anti-infectives market
Leading healthcare fund manager, BioScience Managers, has moved into the rapidly growing anti-infectives market with a US$1m investment into Bulletin Board-listed AmpliPhi Biosciences Corporation (APHB.PK).

AmpliPhi has a proprietary library of bacteriophage, naturally occurring viruses which seek out and lethally target bacteria. Unaffected by antibiotic resistance these viruses are highly specific and have been proven to be safe for humans, animals, fish and plants.

In 2012, AmpliPhi merged with Australian company Special Phage Services, securing additional technology and expertise and adding to the international footprint already established in the USA and the UK.

“Resistance to antibiotics is fast emerging as one of the biggest challenges in the modern healthcare environment. We have high expectations for this investment and we’re pleased to be supporting Australian technology and talent in the context of a much larger international opportunity,” commented Chief Investment Officer Matt McNamara.

In the US over 50% of hospital-acquired infections are caused by drug resistant bacteria, creating a rapidly growing market with few effective solutions.

BioScience Managers has invested US$1m in a $7m private placement, alongside RA Capital Management and Third Security LLC, and will take an active role supporting the company as it grows into an international leader in the anti-infectives market.

“We are very pleased to have the support of these outstanding life science investors,” said Philip J Young, President and Chief Executive Officer of AmpliPhi.  “The financing will allow us to more rapidly advance the development and commercialization of a variety of bacteriophage-containing human therapeutics for use in the treatment of bacterial infections.”

McNamara said, “We are looking forward to supporting AmpliPhi as the company moves forward with its clinical development.  We believe this is an exciting company with the potential to become a market leader with technology that will make a substantial difference to world healthcare.”

Click here for the complete issue.

news A Heroic Voyage — Sydney Brenner's Life in Science
news VeloX, A Minimally Invasive Prosthetic Heart Valve for treating Mitral Regurgitation
news Anti-CD25 monoclonal antibody (90Y-daclizumab) a favorable target towards systemic radio-immunotherapy in Hodgkin's Lymphoma

Credits to Sony Computer Entertainment and click here for behind the scenes.

APBN Editorial Calendar 2015
Trends and Predictions for 2015 Robotics in Healthcare Nutrition Universal Health Coverage
Start-Up Biotech Companies Preventative and Translational Medicine Biofuels ASEAN Economic Community and Asia's Life Sciences Industry
Big Data: Healthcare and Drug Development Antibody Engineering in Japan Christmas Edition
APBN Editorial Calendar 2016
Korea's Biotechnology Industry Nutrition and Allergies: Are we, Too Clean? Medical Devices and Technology: Innovation that leaves an Inspiration Tobacco Smoking: The 'Real' Cost of One Cigarette
Life-Saving Opportunities: A Guide to Regenerative Medicine Occupational Health Water Technology Olympics: Evolution of Sports
Respiratory: Seasonal flu viruses
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy